MDT-AP-2744
Med · Medulloblastoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Med
- cancer_type_detailed
- —
- subtype
- Medulloblastoma
- cancer_type
- Med
- subtype
- Medulloblastoma
- os_event
- false
- age_years
- 4
- sex
- M
- new_clusters
- C3
- umap1_2d
- 5.178873569
- umap2_2d
- 4.171879153
- umap1_3d
- 2.45414355
- umap2_3d
- -1.670381177
- umap3_3d
- -2.352714027
- dataset
- Med-Taylor
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PROTEIN_SECRETION+0.310
- OXIDATIVE_PHOSPHORYLATION+0.200
- XENOBIOTIC_METABOLISM+0.170
- TGF_BETA_SIGNALING+0.160
- TNFA_SIGNALING_VIA_NFKB+0.160
- ADIPOGENESIS+0.150
- FATTY_ACID_METABOLISM+0.120
- P53_PATHWAY+0.110
- PI3K_AKT_MTOR_SIGNALING+0.100
- HYPOXIA+0.090
Top 10 suppressed
- E2F_TARGETS-0.370
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.300
- G2M_CHECKPOINT-0.280
- HEDGEHOG_SIGNALING-0.270
- ANGIOGENESIS-0.250
- APICAL_JUNCTION-0.230
- APICAL_SURFACE-0.220
- BILE_ACID_METABOLISM-0.220
- MITOTIC_SPINDLE-0.170
- INTERFERON_ALPHA_RESPONSE-0.150
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MDT-AP-2996 | Med | Medulloblastoma | 0.776 |
| 2 | BS_9M5XJ10G | Med | Medulloblastoma | 0.725 |
| 3 | TCGA-BH-A18S-01A-11R-A12D-07 | — | B | 0.705 |
| 4 | SRR12202457 | — | — | 0.702 |
| 5 | TCGA-D8-A1JN-01A-11R-A13Q-07 | — | C | 0.694 |
| 6 | BS_DFWFBYSN | Med | Medulloblastoma | 0.685 |
| 7 | TCGA-78-7163-01A-12R-2066-07 | — | cohortA1 | 0.681 |
| 8 | TCGA-GM-A2DM-01A-11R-A180-07 | — | B | 0.676 |
| 9 | TCGA-75-5146-01A-01R-1628-07 | — | cohortA1 | 0.676 |
| 10 | SRR10842356 | — | — | 0.673 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 22 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PROTEIN_SECRETION | 0.310 | Remibrutinib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.200 | Remibrutinib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.170 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.160 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.160 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.150 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.120 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.110 | Idelalisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.100 | Inavolisib | — uncovered |
| HYPOXIA | 0.090 | Idelalisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.090 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.080 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.080 | Cobimetinib | — uncovered |
| HEME_METABOLISM | 0.070 | Temsirolimus | — uncovered |
| IL2_STAT5_SIGNALING | 0.060 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.060 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.050 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.030 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.030 | Idelalisib | — uncovered |
| NOTCH_SIGNALING | 0.020 | Inavolisib | — uncovered |